Association of Delayed Denosumab Dosing with Increased Risk of Fractures: A Population-Based Retrospective Study
Kyoung Min Kim, Seol A Jang, Nam Ki Hong, Chul Sik Kim, Yumie Rhee, Seok Won Park, Steven R Cummings, Gi Hyeon Seo · 2024
Read Association of Delayed Denosumab Dosing with Increased Risk of Fractures: A Population-Based Retrospective Study by Kyoung Min Kim, Seol A Jang, Nam Ki Hong, Chul Sik Kim, Yumie Rhee, Seok Won Park, Steven R Cummings, Gi Hyeon Seo (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11695474.txt.
Description
Kyoung Min Kim and co-authors ask whether late doses of a bone drug raise fracture risk. Their 2024 population study uses Korean national insurance data. Denosumab slows bone loss, but its effect reverses fast once doses stop, which makes timing more than a clerical detail.
Women aged forty-five to eighty-nine who began the drug for osteoporosis between 2017 and 2019 formed the cohort. Later doses were classed from early through on-time to delays of growing length. Nearly one hundred fifty thousand women were tracked, with over two thousand fractures recorded. Even a delay of one to three months carried a clearly higher fracture rate than on-time dosing. The authors urge systems that keep patients on schedule.
Catalog record
| CREATOR | Kyoung Min Kim, Seol A Jang, Nam Ki Hong, Chul Sik Kim, Yumie Rhee, Seok Won Park, Steven R Cummings, Gi Hyeon Seo |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |